The complement system in man is a major mechanism by which immune processes lead to inflammation and tissue damage. When activated, proteins are produced which increase vascular permeability, release vasoactive amines from mast cells and platelets, and mediate cell lysis. Activation of complement may be initiated by a number of factors, which include antigen-antibody complexes, bacterial endotoxin, and various proteolytic enzymes.
In ulcerative colitis and Crohn's disease, immune complexes have been found in the circulation (Doe et al., 1973; Jewell and MacLennan, 1973) ; endotoxin has also been reported in the serum of these patients (Bowen and Kirsner, 1965) . It therefore seems probable that complement activation occurs in these diseases.
The present study investigated the levels of complement components, from both the classical (Clq, C4, C3) and alternative pathways (factor B, C3) of activation, in the sera of patients with ulcerative colitis and Crohn's disease, correlating these with the clinical features. Data on the presence of immune complexes in the same sera were obtained (Hodgson et al., 1977 C3 activation Those sera containing more than 2 g/l of C3 were tested for evidence of C3 activation by two-dimensional immunoelectrophoresis against antihuman C3 (Hyland).
STATISTICAL METHODS
Comparisons between groups were made using Student's t test.
Results
The mean serum levels of Clq, C4, C3, and factorB obtained in the four groups of patients studies are shown in the Table.
Clq
The mean level for patients with ulcerative colitis was significantly higher than the mean level for patients with Crohn's disease (p < 0 025). There were no other significant differences between groups.
C4
There was no significant difference between the hospital patients and the patients with ulcerative colitis or Crohn's disease. The mean level for the healthy control subjects was significantly lower for the hospital control patients (p < 0-05).
C3
Patients with Crohn's disease had a higher mean C3 level than patients with ulcerative colitis or either of the control groups (p < 0-01). The mean for the patients with ulcerative colitis did not differ significantly from the hospital control patients. The mean level for healthy controls was significantly lower than for hospital control patients (p < 0 05).
FACTOR B
Both patients with ulcerative colitis and with Crohn's disease had significantly higher mean factor B levels than either control group (p < 0-05). The mean for Crohn's disease was higher than that for ulcerative colitis (p < 0-025). The two control groups did not differ significantly.
SITE AND EXTENT OF DISEASE
Levels of C3 were significantly higher in patients with ulcerative colitis when the area of colon involved was substantial rather than distal (mean C3 = 1380 ± 40 mg/I and 1260 ± 40 mg/l respectively, p < 0 05). The mean factor B levels were also higher in patients with substantial colitis compared with those with distal colitis (220 ± 9 5 mg/l and 174 + 8 mg/l respectively, P < 0 005). There was no difference between the mean levels of Clq andC4 between these groups. For patients with Crohn's disease, no correlation was found between the site of disease and the mean levels of any of the complement components measured.
ACTIVITY OF DISEASE
For both ulcerative colitis and Crohn's disease, there was a tendency for the levels of C3 and factor B to rise with increasing activity of disease. For C4, a similar correlation was seen only in ulcerative colitis. No correlation with disease activity was found for Clq in either group.
Eighteen patients (11 with ulcerative colitis, seven with Crohn's disease) were studied as they passed from relapse to remission. The levels of C3 and factor B fell significantly (Fig. 1 ) but there were no consistent alterations in the levels of Clq and C4 (Fig. 2) . 
EFFECTS OF THERAPY
There were no differences in the mean levels of any of these complement components for patients on or off systemic corticosteroid therapy. This was so for the whole group of patients with each disease, and also when groups of patients with the same degree of disease activity were compared.
EXTRAINTESTINAL MANIFESTATIONS
In those patients with arthritis or eye or skin complications, there was no tendency for the levels of complement components to fall, and the mean levels did not differ from the mean levels of the disease groups as a whole. Among 17 patients with liver disease (one with inactive cirrhosis, seven with chronic active hepatitis and cirrhosis, six with sclerosing cholangitis, and four with pericholangitis) mean C4 levels were significantly lower (408 ± 34 mg/I) than for patients without liver disease (558 + 26 mg/I, P < 0 05).
IMMUNE COMPLEXES
In patients in whom the presence of immune complexes had been indicated by excessive anticomplementary activity, in the sera (Hodgson et al., 1977) , mean factor B levels were significantly raised (252 + 12 mg/l with excess anticomplementary activity, 199 ± 5 5 mg/l without; P < 0-001). There was no significant difference for Clq or C4; C3 tended to be higher in patients with excess anticomplementary activity (1440 ± 50 mg/l with, 1350 ± 29 mg/l without), but the difference is not significant (p = 0X1).
CORRELATION BETWEEN INDIVIDUAL COMPONENTS
The levels of C4, C3, and factor B correlated positively among the patients with inflammatory bowel disease. The correlations were weak with r values from 0X306 to 0X529, p < 0 001. Clq levels failed to correlate with C3 or factor B, but showed a weak positive correlation with C4 (r = 0-192, p < 0 01). 
Discussion
This study of the serum concentration of four complement proteins in inflammatory bowel diseases confirms the reports of others that the levels tend to be higher when the disease is most active (Ward and Eastwood, 1974; Feinstein etal., 1976) . This was particularly marked for C3 and factor B, and occurred in both ulcerative colitis and Crohn's disease. The levels of these two proteins were higher in Crohn's disease than ulcerative colitis, but there is little reason to believe that this represents a basic difference between the two conditions, as the difficulties in assessing the extent and activity of Crohn's disease clinically are well known.
It is significant that for two of the proteins, C3 and C4, hospital control patients without immunological disorders had a higher mean serum level than healthy control subjects. This difference suggests that minor rises in the serum level of these proteins are non-specific, and common in ill-health. Rises in the levels of C3 and C4 (Ward and Eastwood, 1974) and factor B (Feinstein et al., 1976) in patients with inflammatory bowel disease in remission have been reported, and this has been considered evidence of continuing immunopathology, even when the disease was inactive; however, these workers used healthy subjects as their control group. In this study, the meanlevels of C4,C3, 'and factor B in remission did not differ from hospital control patients, suggesting that significant complement abnormalities are found only with active disease.
Among patients with liver disease, C4 levels were depressed, the same pattern as that recognised among patients with chronic liver disease unassociated with inflammatory bowel disease (Potter et al., 1973) . The significance of the finding is unknown. In patients with joint, skin, and eye lesions, complement levels were not depressed, although there is evidence that these manifestations may be mediated by immune complexes (Hodgson et al., 1977) . The presence of normal serum complement levels with a probable immune complex arthritis is paralleled in rheumatoid arthritis (Hoyeraal and Mellbye, 1974) . Similarly, levels of C4 and Clq were unaltered in patients with excess anticomplementary activity, measured as an index of the presence of immune complexes. Factor B levels were significantly higher among patients with excess anticomplementary activity, and C3 showed a similar trend, but this may merely reflect the tendency of these three factors to correlate with disease activity.
The pattern of rise in the level of complement protein during active disease is that of acute phase reactants. C3 and C4 have been shown to behave in this way in acute inflammatory conditions such as tonsillitis and viral meningitis (Ganrot, 1974) . This pattern is emphasised by the tendency of C4, C3, and factor B, proteins from both the classical and alternative pathway of complement, to move in parallel. The typical pattern of depressed levels of classical pathway components seen in systemic lupus erythematosus (Kohler and ten Bensel, 1969) or alternative pathway components seen in membranoproliferative glomerulonephritis (Gewurz et al., 1969) or brought about by endotoxin (Gewurz et al., 1968) has not been found in inflammatory bowel disease.
In the present study, C3 levels were measured in serum obtained within four hours of bleeding the patient. As the clotting process itself is known to activate C3, it is conceivable that C3 conversion products which diffuse more rapidly in gel, such as C3c, could have given rise to apparently high levels of C3 as measured by the Mancini technique. It is also possible that some C3 conversion occurred during the short period between withdrawing the blood from the patient and the freezing of the serum as a result of ageing. However, studies in our own laboratory have shown that the amount of C3 activation occurring after four hours in serum incubated at room temperature is minimal (Potter, 1975) . Furthermore, no evidence of C3 activation was found in those sera with abnormally high C3 levels.
The determination of serum complement levels, therefore, has not provided evidence for the activation of the complement sequence in patients with inflammatory bowel disease. Nevertheless, other lines of evidence suggest complement activation in patients with ulcerative colitis and Crohn's disease. C3 breakdown products have been reported in the sera of patients with these diseases (Teisberg and Gjone, 1975) , although they have been less frequently found when plasma has been examined (Pepys et al., 1976) . Stronger evidence of C3 activation has come from metabolic studies using purified human C3. These have shown an increase in both the fractional catabolic rate and synthesis rate of C3, compared with control subjects (Hodgson ct al., 1975) . The nature of the factor initiating this activation is uncertain, but antigen-antibody interactions within the diseased mucosa, as well as bacterial endotoxin, seem likely to play a role.
